India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Launch of 20 new medicines expected by 2030
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
US FDA approval based on NEURO-TTRansform Phase III results
Development services for gene and cell therapies is planned to begin first in 2025
Subscribe To Our Newsletter & Stay Updated
